{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:42:56Z","timestamp":1791258176076,"version":"4.1.0"},"reference-count":190,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2015.00550","type":"journal-article","created":{"date-parts":[[2015,10,28]],"date-time":"2015-10-28T10:34:52Z","timestamp":1446028492000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":114,"title":["Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus"],"prefix":"10.3389","volume":"6","author":[{"given":"Timothy A.","family":"Gottschalk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Tsantikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Hibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2015,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(06)92001-X","article-title":"Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease","volume":"92","author":"Fairhurst","year":"2006","journal-title":"Adv Immunol"},{"issue":"11","key":"B2","first-page":"2753","article-title":"Treatment of systemic lupus erythematosus: an update","volume":"57","author":"Petri","year":"1998","journal-title":"Am Fam Physician"},{"issue":"2","key":"B3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.81","article-title":"Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci","volume":"40","author":"Harley","year":"2008","journal-title":"Nat Genet"},{"issue":"2","key":"B4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.semnephrol.2010.01.007","article-title":"Genetic factors predisposing to systemic lupus erythematosus and lupus nephritis","volume":"30","author":"Ramos","year":"2010","journal-title":"Semin Nephrol"},{"issue":"5","key":"B5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","article-title":"Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden","volume":"15","author":"Danchenko","year":"2006","journal-title":"Lupus"},{"issue":"11","key":"B6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/0961203306072311","article-title":"Ethnic and geographical differences in systemic lupus erythematosus: an overview","volume":"15","author":"Lau","year":"2006","journal-title":"Lupus"},{"issue":"24","key":"B7","doi-asserted-by":"publisher","first-page":"10934","DOI":"10.1073\/pnas.92.24.10934","article-title":"Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB\/c mice treated with pristane","volume":"92","author":"Satoh","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"B8","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.2174\/1381612821666150316115727","article-title":"Animal models of lupus and lupus nephritis","volume":"21","author":"Du","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"2","key":"B9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0092-8674(95)90171-X","article-title":"Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease","volume":"83","author":"Hibbs","year":"1995","journal-title":"Cell"},{"issue":"5","key":"B10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/ijr.14.44","article-title":"Role of the Lyn tyrosine kinase in the development of autoimmune disease","volume":"9","author":"Tsantikos","year":"2014","journal-title":"Int J Clin Rheumatol"},{"issue":"4","key":"B11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jaut.2012.06.003","article-title":"Loss of STAT6 promotes autoimmune disease and atopy on a susceptible genetic background","volume":"39","author":"Lau","year":"2012","journal-title":"J Autoimmun"},{"issue":"4","key":"B12","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.4049\/jimmunol.0804346","article-title":"Perturbation of the CD4 T cell compartment and expansion of regulatory T cells in autoimmune-prone Lyn-deficient mice","volume":"183","author":"Tsantikos","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"B13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1074-7613(00)80554-3","article-title":"Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection","volume":"8","author":"Cornall","year":"1998","journal-title":"Immunity"},{"issue":"5","key":"B14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1084\/jem.187.5.807","article-title":"Inhibition of the B cell by CD22: a requirement for Lyn","volume":"187","author":"Smith","year":"1998","journal-title":"J Exp Med"},{"issue":"3","key":"B15","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.4049\/jimmunol.0901878","article-title":"Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6","volume":"184","author":"Tsantikos","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"B16","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.4049\/jimmunol.1103427","article-title":"Genetic interdependence of Lyn and negative regulators of B cell receptor signaling in autoimmune disease development","volume":"189","author":"Tsantikos","year":"2012","journal-title":"J Immunol"},{"issue":"2","key":"B17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1385\/IR:24:2:211","article-title":"Of mice and men: the relevance of the mouse to the study of human SLE","volume":"24","author":"Birmingham","year":"2001","journal-title":"Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"271694","DOI":"10.1155\/2011\/271694","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"Perry","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"11","key":"B19","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/rheumatology\/keh354","article-title":"Autoantibodies, lupus and the science of sabotage","volume":"43","author":"Rahman","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"B20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00467-011-2078-4","article-title":"Autoantibodies in systemic lupus erythematosus","volume":"27","author":"Marks","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"16","key":"B21","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"B22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/ar3528","article-title":"Mechanisms of tissue injury in lupus nephritis","volume":"13","author":"Nowling","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"B23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jbspin.2010.04.010","article-title":"Anti-CRP antibodies in systemic lupus erythematosus","volume":"77","author":"Meyer","year":"2010","journal-title":"Joint Bone Spine"},{"issue":"5","key":"B24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrrheum.2011.37","article-title":"C-reactive protein in rheumatology: biology and genetics","volume":"7","author":"Rhodes","year":"2011","journal-title":"Nat Rev"},{"issue":"2","key":"B25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1172\/JCI117371","article-title":"Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo","volume":"94","author":"Kramers","year":"1994","journal-title":"J Clin Invest"},{"issue":"9","key":"B26","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"B27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12026-012-8270-1","article-title":"TLR7 and TLR9 in SLE: when sensing self goes wrong","volume":"53","author":"Celhar","year":"2012","journal-title":"Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"980286","DOI":"10.1155\/2011\/980286","article-title":"Th subset balance in lupus nephritis","volume":"2011","author":"Miyake","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"594809","DOI":"10.1155\/2011\/594809","article-title":"The role of cytokine in the lupus nephritis","volume":"2011","author":"Iwata","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"B30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5114\/pdia.2014.40954","article-title":"Interleukin-17 in human inflammatory diseases","volume":"31","author":"Shabgah","year":"2014","journal-title":"Postepy Dermatol Alergol"},{"issue":"1","key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2014.05.004","article-title":"Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus","volume":"154","author":"Martin","year":"2014","journal-title":"Clin Immunol"},{"issue":"3","key":"B32","doi-asserted-by":"publisher","first-page":"e0120294","DOI":"10.1371\/journal.pone.0120294","article-title":"Regulation of autoimmune germinal center reactions in lupus-prone BXD2 mice by follicular helper T cells","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"B33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/0961203314567750","article-title":"Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production","volume":"24","author":"Zhang","year":"2015","journal-title":"Lupus"},{"issue":"6","key":"B34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.coi.2012.10.003","article-title":"Developing connections amongst key cytokines and dysregulated germinal centers in autoimmunity","volume":"24","author":"Sweet","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"B35","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"Chang","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"B36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"B37","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/ard.62.5.435","article-title":"Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment","volume":"62","author":"Fiehn","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"B38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jaci.2010.12.1087","article-title":"Current and novel therapeutics in the treatment of systemic lupus erythematosus","volume":"127","author":"Yildirim-Toruner","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3\u20134","key":"B39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaut.2009.02.006","article-title":"Why can\u2019t we find a new treatment for SLE?","volume":"32","author":"Eisenberg","year":"2009","journal-title":"J Autoimmun"},{"issue":"5","key":"B40","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J Immunol"},{"issue":"4","key":"B41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B42","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"B43","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B44","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"B45","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.2217\/imt.14.80","article-title":"Evaluation of epratuzumab as a biologic therapy in systemic lupus erythematosus","volume":"6","author":"Rao","year":"2014","journal-title":"Immunotherapy"},{"issue":"10","key":"B46","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9767","key":"B47","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B48","author":"Jefferson","year":"2011","journal-title":"FDA News Release. FDA Approves Benlysta to Treat Lupus 2011"},{"issue":"2","key":"B49","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell"},{"issue":"7183","key":"B50","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature06664","article-title":"The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response","volume":"452","author":"Muruve","year":"2008","journal-title":"Nature"},{"issue":"9","key":"B51","doi-asserted-by":"publisher","first-page":"5826","DOI":"10.4049\/jimmunol.180.9.5826","article-title":"Danger signaling through the inflammasome acts as a master switch between tolerance and sensitization","volume":"180","author":"Watanabe","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"B52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ki.1996.290","article-title":"Cytokine gene expression in the MRL\/lpr model of lupus nephritis","volume":"50","author":"Lemay","year":"1996","journal-title":"Kidney Int"},{"issue":"2","key":"B53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/08916939609001949","article-title":"IL-1 beta gene expression in B cells derived from the murine MRL\/lpr model of lupus","volume":"24","author":"Mao","year":"1996","journal-title":"Autoimmunity"},{"issue":"4","key":"B54","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/art.38993","article-title":"Lupus nephritis: glycogen synthase kinase 3beta promotion of renal damage through activation of the NLRP3 inflammasome in lupus-prone mice","volume":"67","author":"Zhao","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"B55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.intimp.2013.05.027","article-title":"Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kappaB activation","volume":"17","author":"Zhao","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"B56","first-page":"109","article-title":"IL-1 beta-deficient mice are resistant to induction of experimental SLE","volume":"17","author":"Voronov","year":"2006","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"B57","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/0090-1229(87)90091-2","article-title":"The effect of interleukin 1 on IgG synthesis in systemic lupus erythematosus","volume":"45","author":"Jandl","year":"1987","journal-title":"Clin Immunol Immunopathol"},{"issue":"5","key":"B58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/BF00917107","article-title":"Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus","volume":"9","author":"Tanaka","year":"1989","journal-title":"J Clin Immunol"},{"issue":"2","key":"B59","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/096120339200100209","article-title":"Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers","volume":"1","author":"Alcocer-Varela","year":"1992","journal-title":"Lupus"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08916934.2015.1064399","article-title":"Inflammasome polymorphisms in juvenile systemic lupus erythematosus","volume":"16","author":"Pontillo","year":"2015","journal-title":"Autoimmunity"},{"key":"B61","doi-asserted-by":"publisher","first-page":"C113","DOI":"10.1007\/BF01972739","article-title":"Immunomodulatory activity of recombinant IL-1 receptor (IL-1-R) on models of experimental rheumatoid arthritis","volume":"39","author":"Schorlemmer","year":"1993","journal-title":"Agents Actions"},{"issue":"1","key":"B62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF02887995","article-title":"Study on immunoregulation by interleukin-1 receptor antagonist in NZB\/W F mice","volume":"17","author":"Sun","year":"1997","journal-title":"J Tongji Med Univ"},{"issue":"4","key":"B63","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1136\/ard.2004.025858","article-title":"Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis","volume":"64","author":"Ostendorf","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"B64","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.4049\/jimmunol.1402859","article-title":"Deficient NLRP3 and AIM2 inflammasome function in autoimmune NZB Mice","volume":"195","author":"Sester","year":"2015","journal-title":"J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2014-205496","article-title":"NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-beta receptor signalling","author":"Lech","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"B66","doi-asserted-by":"publisher","first-page":"e000087","DOI":"10.1136\/lupus-2015-000087","article-title":"A highlight from the LUPUS 2014 meeting: eight great ideas","volume":"2","author":"Buyon","year":"2015","journal-title":"Lupus Sci Med"},{"issue":"9","key":"B67","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0961203310371161","article-title":"The interferon-alpha signature of systemic lupus erythematosus","volume":"19","author":"Obermoser","year":"2010","journal-title":"Lupus"},{"issue":"4","key":"B68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum interferon levels in patients with systemic lupus erythematosus","volume":"25","author":"Ytterberg","year":"1982","journal-title":"Arthritis Rheum"},{"issue":"3","key":"B69","first-page":"562","article-title":"Serum levels of interferons in patients with systemic lupus erythematosus","volume":"70","author":"Kim","year":"1987","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"B70","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1191\/096120300674499064","article-title":"Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies","volume":"9","author":"Bengtsson","year":"2000","journal-title":"Lupus"},{"issue":"12","key":"B71","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1136\/ard.2004.033753","article-title":"Type I interferon correlates with serological and clinical manifestations of SLE","volume":"64","author":"Dall\u2019era","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"B72","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/IAI.42.1.368-373.1983","article-title":"Renal deposition of alpha interferon in systemic lupus erythematosus","volume":"42","author":"Panem","year":"1983","journal-title":"Infect Immun"},{"issue":"4","key":"B73","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/art.1780350410","article-title":"Interferon-alpha in lupus psychosis","volume":"35","author":"Shiozawa","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"9","key":"B74","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2169\/internalmedicine.41.754","article-title":"Lupus retinopathy associated with a high IFN-alpha level in the cerebrospinal fluid","volume":"41","author":"Kondo","year":"2002","journal-title":"Intern Med"},{"issue":"2","key":"B75","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.4049\/jimmunol.182.2.1192","article-title":"Potent induction of IFN-alpha and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus","volume":"182","author":"Santer","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"B76","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1365-2796.1990.tb00144.x","article-title":"Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour","volume":"227","author":"Ronnblom","year":"1990","journal-title":"J Intern Med"},{"issue":"12","key":"B77","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00296-009-1188-9","article-title":"Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China","volume":"30","author":"Zhao","year":"2010","journal-title":"Rheumatol Int"},{"issue":"8","key":"B78","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1084\/jem.20050914","article-title":"Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus","volume":"202","author":"Barrat","year":"2005","journal-title":"J Exp Med"},{"issue":"12","key":"B79","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/eji.200737815","article-title":"Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms","volume":"37","author":"Barrat","year":"2007","journal-title":"Eur J Immunol"},{"issue":"3","key":"B80","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2249.2008.03646.x","article-title":"Up-regulated expression of toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus","volume":"152","author":"Komatsuda","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"B81","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)","author":"Kalunian","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"B83","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"B84","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1124\/mol.113.089821","article-title":"Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo","volume":"85","author":"Lamphier","year":"2014","journal-title":"Mol Pharmacol"},{"issue":"4","key":"B85","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting toll-like receptors: emerging therapeutics?","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"B86","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/BF00920636","article-title":"Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases","volume":"13","author":"al-Janadi","year":"1993","journal-title":"J Clin Immunol"},{"issue":"3","key":"B87","first-page":"222","article-title":"Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus","volume":"15","author":"Robak","year":"2004","journal-title":"Eur Cytokine Netw"},{"issue":"10","key":"B88","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1177\/0961203312451200","article-title":"Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus","volume":"21","author":"Rana","year":"2012","journal-title":"Lupus"},{"issue":"3","key":"B89","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/03009740500417791","article-title":"T cell cytokine imbalance towards production of IFN-gamma and IL-10 in NZB\/W F1 lupus-prone mice is associated with autoantibody levels and nephritis","volume":"35","author":"Enghard","year":"2006","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"B90","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1084\/jem.166.3.798","article-title":"In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon","volume":"166","author":"Jacob","year":"1987","journal-title":"J Exp Med"},{"issue":"2","key":"B91","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.38955","article-title":"Function of the Th17\/interleukin-17A immune response in murine lupus nephritis","volume":"67","author":"Schmidt","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"B92","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.4049\/jimmunol.160.8.3713","article-title":"IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice","volume":"160","author":"Haas","year":"1998","journal-title":"J Immunol"},{"issue":"8","key":"B93","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1084\/jem.20100086","article-title":"Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice","volume":"207","author":"Scapini","year":"2010","journal-title":"J Exp Med"},{"issue":"3","key":"B94","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1046\/j.1365-2249.2000.01369.x","article-title":"Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE)","volume":"122","author":"Csiszar","year":"2000","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"B95","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.4049\/jimmunol.181.3.2211","article-title":"Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator\/B cell-activating factor\/TNF ligand superfamily-13B","volume":"181","author":"Harigai","year":"2008","journal-title":"J Immunol"},{"issue":"6","key":"B96","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/art.30313","article-title":"Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-gamma production in patients with active disease","volume":"63","author":"Hervier","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"8","key":"B97","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40265-015-0394-x","article-title":"Targeting interferons in systemic lupus erythematosus: current and future prospects","volume":"75","author":"Mathian","year":"2015","journal-title":"Drugs"},{"issue":"10","key":"B98","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/art.39248","article-title":"Blockade of interferon-gamma (IFN-gamma) normalizes IFN regulated gene expression and serum CXCL10 (IP-10) in subjects with systemic lupus erythematosus (SLE)","volume":"67","author":"Welcher","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"B99","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.autrev.2011.05.001","article-title":"Therapeutic blockade of TNF in patients with SLE-promising or crazy?","volume":"11","author":"Aringer","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"B100","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.cyto.2011.08.026","article-title":"The role of tumor necrosis factor-alpha (TNF-alpha) in the pathogenesis of systemic lupus erythematosus","volume":"56","author":"Postal","year":"2011","journal-title":"Cytokine"},{"issue":"9","key":"B101","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/rheumatology\/ket428","article-title":"The association of cytokines with disease activity and damage scores in systemic lupus erythematosus patients","volume":"53","author":"McCarthy","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"B102","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","article-title":"Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis","volume":"5","author":"Taylor","year":"2009","journal-title":"Nat Rev"},{"issue":"10","key":"B103","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B104","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/DHPS.S28801","article-title":"Clinical use of anti-TNF therapy and increased risk of infections","volume":"5","author":"Ali","year":"2013","journal-title":"Drug Healthc Patient Saf"},{"key":"B105","doi-asserted-by":"publisher","first-page":"465898","DOI":"10.1155\/2010\/465898","article-title":"Anti-TNF-alpha therapies in systemic lupus erythematosus","volume":"2010","author":"Zhu","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"8","key":"B106","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/0961203309102557","article-title":"Efficacy and safety of infliximab in active SLE: a pilot study","volume":"18","author":"Uppal","year":"2009","journal-title":"Lupus"},{"issue":"9957","key":"B107","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"B108","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.disamonth.2003.10.001","article-title":"Antiphospholipid syndrome","volume":"49","author":"Gezer","year":"2003","journal-title":"Dis Mon"},{"issue":"11","key":"B109","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"MacKay","year":"1999","journal-title":"J Exp Med"},{"issue":"7","key":"B110","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/art.21138","article-title":"BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus","volume":"52","author":"Stohl","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"B111","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:61313::AID-ART2233.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B112","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4049\/jimmunol.166.1.6","article-title":"Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus","volume":"166","author":"Zhang","year":"2001","journal-title":"J Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1196\/annals.1313.004","article-title":"BAFF overexpression is associated with autoantibody production in autoimmune diseases","volume":"1050","author":"Pers","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"B114","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0961203306071871","article-title":"B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time","volume":"15","author":"Becker-Merok","year":"2006","journal-title":"Lupus"},{"issue":"8","key":"B115","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/art.23678","article-title":"Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus","volume":"58","author":"Petri","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"B116","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1172\/JCI26385","article-title":"Similarities and differences between selective and nonselective BAFF blockade in murine SLE","volume":"116","author":"Ramanujam","year":"2006","journal-title":"J Clin Invest"},{"issue":"6B","key":"B117","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/j.1582-4934.2009.00817.x","article-title":"Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice","volume":"14","author":"Ding","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"5","key":"B118","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/art.27368","article-title":"Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice","volume":"62","author":"Ramanujam","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"B119","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/intimm\/dxl053","article-title":"Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy","volume":"18","author":"Yoshimoto","year":"2006","journal-title":"Int Immunol"},{"issue":"7","key":"B120","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/rheumatology\/kem097","article-title":"Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production","volume":"46","author":"Morimoto","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"B121","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/art.24628","article-title":"Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus","volume":"60","author":"Chu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"B122","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1002\/eji.1830210932","article-title":"Expansion and high proliferative potential of the macrophage system throughout life time of lupus-prone NZB\/W and MRL lpr\/lpr mice. Lack of down-regulation of extramedullar macrophage proliferation in the postnatal period","volume":"21","author":"Muller","year":"1991","journal-title":"Eur J Immunol"},{"issue":"12","key":"B123","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0961203309104430","article-title":"Splenic volume in systemic lupus erythematosus","volume":"18","author":"Harris","year":"2009","journal-title":"Lupus"},{"issue":"1\u20132","key":"B124","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.imbio.2004.03.001","article-title":"IL-3 in dendritic cell development and function: a comparison with GM-CSF and IL-4","volume":"209","author":"Lutz","year":"2004","journal-title":"Immunobiology"},{"issue":"3","key":"B125","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000236414","article-title":"Interleukin-3 immunoassay in systemic lupus erythematosus patients: preliminary data","volume":"100","author":"Fishman","year":"1993","journal-title":"Int Arch Allergy Immunol"},{"issue":"338","key":"B126","doi-asserted-by":"publisher","first-page":"ra77","DOI":"10.1126\/scisignal.2005105","article-title":"The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice","volume":"7","author":"Infantino","year":"2014","journal-title":"Sci Signal"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.196","article-title":"IL-3 contributes to development of lupus nephritis in MRL\/lpr mice","author":"Renner","year":"2015","journal-title":"Kidney Int"},{"issue":"8","key":"B128","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"issue":"3","key":"B129","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/ard.2007.076117","article-title":"Increase in the level of macrophage colony-stimulating factor in patients with systemic lupus erythematosus","volume":"67","author":"Yang","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"B130","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3899\/jrheum.090662","article-title":"Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases","volume":"37","author":"Maruyama","year":"2010","journal-title":"J Rheumatol"},{"issue":"3","key":"B131","first-page":"403","article-title":"Glomerular expression of macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in patients with various forms of glomerulonephritis","volume":"75","author":"Matsuda","year":"1996","journal-title":"Lab Invest"},{"issue":"8","key":"B132","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/ndt\/16.8.1638","article-title":"Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis","volume":"16","author":"Isbel","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"B133","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00011-007-6147-x","article-title":"Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare","volume":"56","author":"Tian","year":"2007","journal-title":"Inflamm Res"},{"issue":"2","key":"B134","first-page":"255","article-title":"Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice","volume":"139","author":"Yui","year":"1991","journal-title":"Am J Pathol"},{"issue":"7","key":"B135","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.4049\/jimmunol.173.7.4744","article-title":"Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice","volume":"173","author":"Lenda","year":"2004","journal-title":"J Immunol"},{"issue":"12","key":"B136","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1681\/ASN.2009050499","article-title":"Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis","volume":"20","author":"Menke","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaut.2014.11.007","article-title":"Macrophage depletion ameliorates nephritis induced by pathogenic antibodies","volume":"57","author":"Chalmers","year":"2015","journal-title":"J Autoimmun"},{"issue":"4","key":"B138","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.molimm.2013.05.002","article-title":"GM-CSF as a therapeutic target in inflammatory diseases","volume":"56","author":"van Nieuwenhuijze","year":"2013","journal-title":"Mol Immunol"},{"issue":"5","key":"B139","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/1529-0131(199805)41:5838::AID-ART103.0.CO;2-S","article-title":"Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus","volume":"41","author":"Horwitz","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"3","key":"B140","first-page":"121","article-title":"[Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy]","volume":"51","author":"Fiehn","year":"1992","journal-title":"Z Rheumatol"},{"issue":"4","key":"B141","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1191\/0961203304lu1009oa","article-title":"Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption","volume":"13","author":"Willeke","year":"2004","journal-title":"Lupus"},{"issue":"6","key":"B142","first-page":"531","article-title":"[Effect of G-CSF and GM-CSF on expression of TNF-alpha mRNA and CD69 and secretion of IgG in peripheral blood mononuclear cells from systemic lupus erythematosus patients]","volume":"10","author":"Lu","year":"2002","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B143","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/978-1-4615-1971-3_86","article-title":"Low reactivity of peripheral blood dendritic cells respond to IL-1 and GM-CSF in SLE patients","volume":"378","author":"Akiyama","year":"1995","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"B144","first-page":"152","article-title":"Distinctive effects of G-CSF, GM-CSF and TNFalpha on neutrophil apoptosis in systemic lupus erythematosus","volume":"23","author":"Armstrong","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"B145","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","article-title":"MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"74","author":"Behrens","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"B146","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1916","article-title":"Interleukin-6: discovery of a pleiotropic cytokine","volume":"8","author":"Kishimoto","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"B147","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","article-title":"Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus","volume":"27","author":"Chun","year":"2007","journal-title":"J Clin Immunol"},{"issue":"3\u20134","key":"B148","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cyto.2006.07.023","article-title":"Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity","volume":"35","author":"Sabry","year":"2006","journal-title":"Cytokine"},{"issue":"3","key":"B149","first-page":"281","article-title":"Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus","volume":"8","author":"Robak","year":"1997","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"B150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","article-title":"Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis","volume":"147","author":"Linker-Israeli","year":"1991","journal-title":"J Immunol"},{"issue":"3","key":"B151","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000045663","article-title":"Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis","volume":"85","author":"Tsai","year":"2000","journal-title":"Nephron"},{"issue":"6","key":"B152","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/096120339600500603","article-title":"Serum and urinary interleukin-6 in systemic lupus erythematosus","volume":"5","author":"Peterson","year":"1996","journal-title":"Lupus"},{"issue":"3","key":"B153","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/j.1365-2567.2007.02649.x","article-title":"Interleukin-6 is responsible for aberrant B-cell receptor-mediated regulation of RAG expression in systemic lupus erythematosus","volume":"122","author":"Hillion","year":"2007","journal-title":"Immunology"},{"issue":"12","key":"B154","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1177\/0961203315588971","article-title":"Association of the interleukin-6 polymorphisms with systemic lupus erythematosus: a meta-analysis","volume":"24","author":"Cui","year":"2015","journal-title":"Lupus"},{"issue":"3","key":"B155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jlb.53.3.294","article-title":"Expansion of the liver-associated macrophage system in systemic lupus erythematosus-prone NZB\/W mice","volume":"53","author":"Emmendorffer","year":"1993","journal-title":"J Leukoc Biol"},{"issue":"3","key":"B156","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/intimm\/3.3.273","article-title":"Age-associated increase in interleukin 6 in MRL\/lpr mice","volume":"3","author":"Tang","year":"1991","journal-title":"Int Immunol"},{"issue":"11","key":"B157","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10067-014-2717-9","article-title":"Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model","volume":"33","author":"Mao","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"1","key":"B158","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4049\/jimmunol.178.1.271","article-title":"IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions","volume":"178","author":"Wan","year":"2007","journal-title":"J Immunol"},{"issue":"19","key":"B159","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1182\/blood-2008-12-192559","article-title":"Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals","volume":"113","author":"Maeda","year":"2009","journal-title":"Blood"},{"issue":"1","key":"B160","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3899\/jrheum.090194","article-title":"Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus","volume":"37","author":"Cash","year":"2010","journal-title":"J Rheumatol"},{"issue":"9","key":"B161","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1002\/art.38716","article-title":"Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjogren\u2019s syndrome features in lupus-prone Sle1.Yaa mice","volume":"66","author":"Maier-Moore","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6\u20137","key":"B162","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur J Cell Biol"},{"issue":"10","key":"B163","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/art.38061","article-title":"Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice","volume":"65","author":"Tsantikos","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"B164","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1359-6446(97)01164-1","article-title":"IL-6 as a drug discovery target","volume":"3","author":"Stein","year":"1998","journal-title":"Drug Discov Today"},{"issue":"4","key":"B165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02888108","article-title":"Immunoregulation of lupus-like NZB\/W F1 mice by anti-murine IL-1 alpha, IL-6 antibodies","volume":"16","author":"Liu","year":"1996","journal-title":"J Tongji Med Univ"},{"issue":"2","key":"B166","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1172\/JCI117373","article-title":"Interleukin 6 promotes murine lupus in NZB\/NZW F1 mice","volume":"94","author":"Finck","year":"1994","journal-title":"J Clin Invest"},{"issue":"3","key":"B167","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1365-2567.2006.02433.x","article-title":"Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus","volume":"119","author":"Liang","year":"2006","journal-title":"Immunology"},{"issue":"8","key":"B168","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/blood.V86.8.3123.3123","article-title":"Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments","volume":"86","author":"Lu","year":"1995","journal-title":"Blood"},{"issue":"3","key":"B169","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5414\/CP201785","article-title":"Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects","volume":"51","author":"Zhuang","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"B170","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","article-title":"Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study","volume":"72","author":"Xu","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"B171","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","article-title":"Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"B172","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B173","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1681\/ASN.V4158","article-title":"Interleukin-6 receptor blockage ameliorates murine lupus nephritis","volume":"4","author":"Kiberd","year":"1993","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"B174","first-page":"851","article-title":"Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth","volume":"53","author":"Sato","year":"1993","journal-title":"Cancer Res"},{"issue":"4","key":"B175","doi-asserted-by":"publisher","first-page":"788.e","DOI":"10.1016\/j.clinthera.2012.02.014","article-title":"Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor","volume":"34","author":"Navarro-Millan","year":"2012","journal-title":"Clin Ther"},{"issue":"2","key":"B176","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"B177","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/annrheumdis-2012-201310","article-title":"Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus","volume":"72","author":"Shirota","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"B178","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur J Biochem"},{"issue":"6","key":"B179","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","article-title":"Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130","volume":"171","author":"Nowell","year":"2003","journal-title":"J Immunol"},{"issue":"5","key":"B180","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/art.21818","article-title":"Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis","volume":"54","author":"Richards","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"B181","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/ATVBAHA.111.229435","article-title":"Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice","volume":"32","author":"Schuett","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"26","key":"B182","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.2174\/092986711796957284","article-title":"Small molecule inhibitors of STAT3 for cancer therapy","volume":"18","author":"Zhao","year":"2011","journal-title":"Curr Med Chem"},{"issue":"1","key":"B183","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4049\/jimmunol.1301513","article-title":"Therapeutic efficacy of suppressing the Jak\/STAT pathway in multiple models of experimental autoimmune encephalomyelitis","volume":"192","author":"Liu","year":"2014","journal-title":"J Immunol"},{"issue":"7","key":"B184","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.4049\/jimmunol.1101228","article-title":"Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2","volume":"187","author":"Lu","year":"2011","journal-title":"J Immunol"},{"issue":"4","key":"B185","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2217\/imt.12.20","article-title":"JAK2 inhibition in murine systemic lupus erythematosus","volume":"4","author":"Tagoe","year":"2012","journal-title":"Immunotherapy"},{"issue":"6","key":"B186","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1177\/0961203315573347","article-title":"DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184","volume":"24","author":"van Vollenhoven","year":"2015","journal-title":"Lupus"},{"issue":"2","key":"B187","first-page":"98","article-title":"Is B cell-targeted therapy effective in systemic lupus erythematosus?","volume":"17","author":"Paran","year":"2015","journal-title":"Isr Med Assoc J"},{"issue":"8","key":"B188","doi-asserted-by":"publisher","first-page":"e0135081","DOI":"10.1371\/journal.pone.0135081","article-title":"Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB\/W F1 mice","volume":"10","author":"Khodadadi","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"B189","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/art.38907","article-title":"Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus","volume":"67","author":"Lin","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1\u20132","key":"B190","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.cellimm.2014.03.017","article-title":"Combination of TACI-IgG and anti-IL-15 treats murine lupus by reducing mature and memory B cells","volume":"289","author":"Ma","year":"2014","journal-title":"Cell Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T02:34:10Z","timestamp":1718159650000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fimmu.2015.00550\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,28]]},"references-count":190,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2015.00550","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,28]]}}}